TITAN PHARMACEUTICALS INC : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

Item 7.01. Regulation FD Disclosure

On November 8, 2021, Titan Pharmaceuticals, Inc. (the "Company") announced that additional positive data from an ongoing in vivo study of its human kappa-opioid receptor agonist ("TP-2021") ProNeura®-based implant in an established 5'-guanidinonaltrindole (5'-GNTI) itch-induced mouse model had been reported in a presentation given earlier in the day at the Society for Neuroscience 2021 Meeting.

A copy of the slide presentation, which will be posted on the Company's website, is attached hereto as Exhibit 99.1 and incorporated herein by reference. The presentation is being furnished pursuant to Item 7.01 of this Current Report and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. This information shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.

Item 8.01. Other Events.

On November 8, 2021, the Company announced the presentation of data from an ongoing in vivo study of its TP-2021 ProNeura®-based implant. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is filed herewith:

 Exhibit Description
Number
  99.1     Presentation at the Society of Neuroscience
  99.2     Press release
104      Cover Page Interactive Data File (embedded within the Inline XBRL document)




                                       2

© Edgar Online, source Glimpses